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Abstract: During the last years, liposomes (microparticulate phospholipid vesicles) have been 
used with growing success as pharmaceutical carriers for antineoplastic drugs. Fields of appli-
cation include lipid-based formulations to enhance the solubility of poorly soluble antitumor 
drugs, the use of pegylated liposomes for passive targeting of solid tumors as well as vector-
conjugated liposomal carriers for active targeting of tumor tissue. Such formulation and drug 
targeting strategies enhance the effectiveness of anticancer chemotherapy and reduce at the 
same time the risk of toxic side-effects. The present article reviews the principles of different 
liposomal technologies and discusses current trends in this ﬁ  eld of research.
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Passive targeting of solid tumors using liposomal 
carriers
Conventional liposomes
For highly lipophilic drugs, such as many antineoplastic agents, speciﬁ  c formulation 
strategies are needed to allow for oral or parenteral administration. Liposomes have 
been used traditionally as a formulation strategy to assist in formulation of poorly-
soluble therapeutic agents. They can be deﬁ  ned as particulate drug carriers, which are 
formed spontaneously by dispersion of phospholipids in aqueous media. The resulting 
closed membrane structures can accommodate amphiphilic or lipophilic drugs incor-
porated into or associated with the lipid bilayer, as opposed to direct encapsulation or 
active entrapment of hydrophilic compounds within the aqueous inner compartment 
of the vesicles. Stability of the membrane bilayer as well as retention of incorporated 
drugs depends thereby on lipid composition and cholesterol content of the liposomal 
membranes. Liposomes with a deﬁ  ned and uniform size can be produced by different 
methods such as sonication or extrusion through polycarbonate ﬁ  lter membranes. Their 
minimal size of 25–100 nm is determined by the maximum possible packing of head-
groups in the inner leaﬂ  et of the membrane bilayer as the curvature of the membrane 
increases with decreasing radius. Potential advantages of liposomal formulations are 
twofold: First, concentrations of lipophilic drugs in aqueous media can be increased 
considerably using liposomal formulations. Second, liposomal carriers have a protective 
effect on incorporated drugs by preventing their enzymatic degradation (Krishna and 
Mayer 1999). The antifungal antibiotic amphotericin B is one of the ﬁ  rst examples of 
a marketed drug, which made use of this formulation principle for intravenous infu-
sion (Gulati et al 1998). The stability and shelf-life of such drug formulations can be 
extended from several months to years by lyophilization (Stevens and Lee 2003).
Liposomal carriers have a strong impact on pharmacokinetics and tissue distribu-
tion of incorporated drugs. This may lead to enhanced efﬁ  cacy as well as reduced International Journal of Nanomedicine 2008:3(1) 22
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toxic side-effects of antitumor drugs. Clinical trials have 
demonstrated a reduced risk of cardiotoxicity of liposomal 
doxorubicin as compared to the free drug while preserving 
antitumor activity (Ewer et al 2004). A major draw-back of 
conventional liposomes is their rapid uptake and accumu-
lation by phagocytic cells of the mononuclear phagocyte 
system (reticuloendothelial system or RES) after systemic 
administration (Frank 1993). The major organs of accumula-
tion are the liver and the spleen due to their rich blood supply 
and the abundance of tissue-resident phagocytic cells. Such 
an unwanted macrophage targeting during chemotherapy 
may be problematic since it may lead to partial depletion 
of macrophages and interfere with important host-defense 
functions of this cell type (Daemen et al 1995). On the other 
hand, passive targeting of organs such as spleen and liver 
may offer as well some advantages with respect to tumor 
chemotherapy: First, the marked increase in tissue retention 
and accumulation of liposomal drugs may lead in the case of 
lipophilic anticancer drugs to retarded removal of the drugs 
from the circulation (Juliano and Stamp 1978). In these stud-
ies, two- to tenfold higher plasma exposures of the antitumor 
agents vinblastine, actinomycin, cytosine arabinoside and 
daunomycin were observed in rats 3 hours after intravenous 
administration as compared to control rats treated with con-
ventional formulations of these drugs. Second, cytokines 
and other immunomodulators have been incorporated in 
liposomes and were used to activate macrophages and to 
render them tumorcidal (Daemen 1992). The application 
of such liposome-encapsulated macrophage activators for 
the treatment of metastatic tumors was explored recently in 
clinical trials (Worth et al 1999).
Sterically stabilized liposomes
Different methods have been proposed to increase the 
half-life of liposomes in the circulation. They include the 
use of synthetic phospholipids, which are conjugated to 
gangliosides (such as monosialoganglioside GM1 derived 
from bovine brain (Allen and Chonn 1987)) or polyethylene 
glycol (PEG) (Klibanov et al 1990; Papahadjopoulos et al 
1991; Woodle et al 1992; Uster et al 1996). Grafting of the 
liposome with the inert and biocompatible polymer PEG 
leads to the formation of a protective, hydrophilic layer on 
the surface of the liposomes. This modiﬁ  cation prevents 
the recognition of liposomes by opsonins (ie, antibodies 
or components of the complement system) and therefore 
reduces their clearance by cells of the RES (Moghimi and 
Patel 1992). Such pegylated liposomes are therefore often 
referred to as ‘sterically stabilized’ or ‘stealth’ liposomes 
(Lasic and Papahadjopoulos 1995). In humans, pegylation of 
liposomes results in an up to 50-fold decrease in the volume 
of distribution to values similar to the plasma volume (from 
200 to 4.5 l), a 200-fold decrease in systemic plasma clear-
ance from 22 to 0.1 l/hour and a nearly 100-fold increase in 
area under the time-concentration curve (Allen 1994). Using 
pegylated phospholipids, the apparent terminal half-life of 
such long-circulating liposomes can be extended in humans 
from a time-scale in minutes to days (Lasic 1996).
The protective effect of pegylation and the resulting 
extension of the plasma half-life in vivo correlates with the 
thickness of the PEG-coating. Experiments with polymer-
somes composed of synthetic pegylated block polymers 
demonstrates that plasma half-life of pegylated nanoparticles 
scales indeed with the length of the PEG polymer chain 
(Photos et al 2003). On theoretical grounds, a thickness of 
a PEG coating of 5 to 10 per cent of the particle diameter is 
needed to achieve effective steric stabilization (Lasic 1996). 
Other studies explored the thickness of a PEG coating by 
direct measurement of PEG-tethered ligand-receptor inter-
action potentials using a surface forces apparatus (Wong 
et al 1997). The length of an extended PEG chain with a 
molecular weight of 2000 Da (PEG-2000) was thereby 
demonstrated to be in the range of 16 nm whereas the thick-
ness of a coiled PEG-2000 chain was 5 nm. Based on these 
considerations, it can be concluded that coating of 100 nm 
liposomes with PEG-2000 should lead to effective steric 
stabilization in vivo.
Pegylated liposomes are biocompatible, inert and are 
characterized by a long half-life in the plasma compartment 
in vivo. As outlined above, they show minimal interactions 
with tissues and organs after systemic administration. Due 
to their big particulate size, long-circulating PEG-liposomes 
can not penetrate across continuous or fenestrated normal 
blood vessels since permeability in these vessels is restricted 
to molecules with a molecular weight of more than 5 kDa 
in peripheral tissues and 70 kDa in the kidney (correspond-
ing to a glomerular ﬁ  ltration cut-off for cationized proteins 
such as ferritin of 14 nm) (Kanwar et al 1991; Maeda 2001), 
respectively. However, within pathological tissues such as 
inﬂ  ammatory or solid tumor tissues, the vascular perme-
ability increases and therefore allows for extravasation of 
macromolecules including plasma proteins and pegylated 
liposomes. In such tissues, macromolecules up to a molecu-
lar weight of approximately 4000 kDa (corresponding to a 
particulate size of 500 nm) are trapped within the interstitial 
tissue space (Yuan et al 1995). This phenomenon has been 
studied extensively and has been termed the tumor-selective International Journal of Nanomedicine 2008:3(1) 23
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enhanced permeability and retention (EPR) effect (Maeda 
et al 2000). These unique properties of solid tumor tissue in 
combination with the extended circulation half-life of steri-
cally stabilized liposomes have been exploited clinically for 
passive tumor tissue targeting (Gabizon et al 1994).
Clinical use of pegylated liposomes
Liposomal drug formulations offer the possibility to increase 
efﬁ  cacy while reducing toxic side effects of cytotoxic chemo-
therapeutic drugs. At present, several liposomal anticancer 
drugs are available in the clinic or are in advanced stages of 
clinical development (Park et al 2004; Hofheinz et al 2005). 
Approved drugs include pegylated liposomal doxorubicin 
(Doxil/Caelyx by Alza/Johnson and Johnson in the US and 
Schering-Plough outside the US), non-pegylated liposomal 
doxorubicin (Myocet by Elan), liposomal daunorubicin 
(DaunoXome by Gilead), liposomal cytarabine (DepoCyte by 
Skye Pharma/Enzon/Mundipharma) and liposomal cisplatin 
(Lipoplatin by Regulon). Liposomal formulations of anthracy-
clines are used for the treatment of ovarian and breast cancer 
or HIV associated Kaposi’s sarcoma. DepoCyte was approved 
for the treatment of lymphomas with meningeal spread and is 
the only liposomal drug administered by intrathecal infusion. 
Lipoplatin is used for the treatment of epithelial malignancies 
(Stathopoulos et al 2005). The clinical use of liposomal formu-
lations of conventional cytostatic drugs was focused initially 
on anthracyclines since these cationic amphiphiles allow for an 
efﬁ  cient and stable liposomal entrapment. More importantly, 
anthracyclines bear a high risk for acute and cumulative car-
diotoxicity (resulting in cardiomyopathy) limiting their use. 
This problem may be addressed using appropriate liposomal 
formulations (Gabizon 2001; Waterhouse et al 2001) since an 
altered pharmacokinetics of liposomal anthracyclines offers 
the possibility to avoid high plasma peaks owing to the drug 
retention within the liposomal formulation. In addition, a 
reduced distribution of the liposomal anthracyclines to the 
heart muscle is observed using pegylated liposomes. Table 1 
provides a summary of pharmacokinetic properties of com-
mercial pegylated and non-pegylated liposomal doxorubicin 
in comparison to the free drug demonstrating the signiﬁ  cant 
differences between the different formulation principles. As 
outlined above, pegylated liposomes show minimal interac-
tions with non-diseased tissues leading to both a low systemic 
plasma clearance as well as a low volume of distribution 
of 0.03–0.05 L/kg (Table 1), which corresponds to values 
obtained for commonly used plasma volume markers or human 
IgG antibodies (Lobo et al 2004). Consequently, pegylated 
liposomal anthracyclines show a signiﬁ  cantly lower risk of 
cardiotoxicity (Ewer et al 2004). This site avoidance of a drug 
sensitive tissue is paralleled by an enhanced drug deposition 
in tumor tissue (passive tumor targeting) leading to a pharma-
codynamic advantage as compared to the free drug (Gabizon 
et al 2006). Thus, the improved therapeutic index results in this 
case from both enhanced efﬁ  cacy and reduced toxicity.
Vector-mediated tumor targeting 
using liposomal carriers
Receptor-mediated tumor targeting
Tumor cells are often characterized by a speciﬁ  c expression 
pattern of membrane associated proteins such as receptors, 
membrane transport systems or adhesion molecules. Provided 
that these structures are accessible from the extracellular 
space, such properties can be exploited for an active targeting 
of diseased cells and tissues using speciﬁ  c effector molecules. 
The concept of active targeting has the potential to combine 
the advantage of an increased therapeutic efﬁ  cacy with a 
reduced risk for adverse side-effects in non-diseased tissues. 
With the arrival of genetic engineering technologies, which 
made it possible to design chimeric mouse-human mono-
clonal antibodies or recombinant peptidic receptor ligands, 
the clinical use of these active tumor targeting strategies 
has become reality. During the last years, several monoclo-
nal antibodies were developed and FDA-approved for the 
active targeting of various tumors (Imai and Takaoka 2006). 
Examples include Trastuzumab (Herceptin), a monoclonal 
antibody for the treatment of HER-2/neu-positive breast can-
cer (Baselga 2000), Rituximab (Mabthera) for the treatment 
of CD20 expressing lymphoproliferative cells (McLaughlin 
Table 1 Pharmacokinetic properties in human of commercial 
preparations of doxorubicin (DOX). Free doxorubicin is com-
pared to doxorubicin encapsulated in conventional liposomes 
(Myocet) and doxorubicin encapsulated in pegylated liposomes 
(Doxil, Caelyx). Liposome diameter: 85 to 150 nm. Data nor-
malisation using an average body surface area of 1.7 m2 and an 
average body weight of 70 kg. Examples of representative studies 
(Hamilton et al 2002; Gabizon et al 2003; Mross et al 2004).
 Free  DOX  Myocet  Doxil/Caelyx
   (non-pegylated    (pegylated
   liposomal  DOX)  liposomal  DOX)
Dose (mg/kg)  1.2  1.8  1.5
AUC (mg.h/L)  3.5  19.4  4082
Clearance (ml/h)  25’300  9’520  23
Vss (L)  365  139  3.0
Half-life (h)  0.06/10.4a  1/52.6a 84
aTwo elimination phases.International Journal of Nanomedicine 2008:3(1) 24
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et al 1998) or Alemtuzumab (Campath) for the treatment of 
B- and T-cell hematological tumors being characterized by 
the expression of the CD52 surface antigen (Flynn and Byrd 
2000). The mechanisms of an antibody-based cancer therapy 
can be twofold: First, a direct action by blocking or stimulating 
the function of target receptors, eg, inhibition of signaling by 
the human epidermal growth factor receptor 2 (HER-2/neu) by 
Herceptin leading to cell growth inhibition and apoptosis of the 
target cell. Second, immune-mediated elimination of tumor cells 
by IgG mediated mechanisms including antibody-dependent 
cellular toxicity, complement-dependent cytotoxicity and 
cell mediated cytotoxicity (eg, phagocytosis by macrophages 
or cytolysis by natural killer cells after recruitment of these 
immune-effector cells) (Imai and Takaoka 2006). The efﬁ  cacy 
of such therapeutic antibodies can be increased by combina-
tion with a conventional chemotherapy. Alternatively, the 
antibodies can be linked directly to a toxin in order to guide 
the cytotoxic drug to the target tumor tissue. Experimental 
systems were used to study conjugates between targeting 
antibodies and small molecules such as the antineoplastic 
drug daunomycin (Sinkule et al 1991). Clinical trials have 
explored the pharmacological effects of conjugates between 
antibodies and potent plant toxins such as a deglycosylated 
ricin A-chain (Pastan and Kreitman 1998; Schnell et al 
2003). Such targeting strategies using speciﬁ  c monoclonal 
antibodies as targeting vectors are of great interest. However, 
a major draw-back of these technologies is the limited carry-
ing capacity of the monoclonal antibody vector since a very 
limited amount of effector molecules only can be coupled 
directly to a targeting vector without interfering with the 
antigen-recognition by the antibody.
Vector-conjugated liposomes
The pharmacokinetic properties of liposomes can be modu-
lated by speciﬁ  c modiﬁ  cations of the liposome surface. 
Besides direct chemical modiﬁ  cations of the phospholipid 
headgroups (such as the introduction of surface charges or 
hydrophilic groups (Gabizon and Papahadjopoulos 1992)), 
conjugation of proteins, peptides or other macromolecules to 
the liposome surface can be achieved. Chemical conjugation 
techniques provide thereby a stable link between the liposo-
mal phospholipids and a speciﬁ  c targeting vector (Hansen 
et al 1995; Torchilin 2005). The availability of pegylated 
liposomes made the development of vector-conjugated 
liposomes possible since the unique properties of these 
long-circulating liposomes can be combined with those of 
a targeting vector of choice within one preparation. These 
properties include ideally:
•  Favorable pharmacokinetic properties due to minimal 
interactions with non-targeted tissues or organs
•  High selectivity towards a biological target increasing 
drug efﬁ  cacy and safety
•  A high transport capacity since high concentrations of 
drug molecules can be achieved within the liposomal 
carrier to be transported using a limited number of con-
jugated targeting vectors
•  Protection from enzymatic degradation of the liposomal 
cargo within the liposome
•  High biocompatibility and therefore a presumably low 
immunogenicity of the liposomal carrier.
Initial attempts to realize the potential of this technology 
used coupling procedures where a targeting receptor was 
conjugated directly to the surface of the pegylated liposome. 
Such a co-immobilization of PEG and the vector on the same 
liposome, however, can lead to poor target recognition due 
to steric hindrance by the hydrophilic PEG corona (Schnyder 
and Huwyler 2005). It has therefore been proposed to use 
PEG as a spacer by coupling targeting vectors to the distal 
end of pegylated phospholipids (Blume et al 1993; Allen 
et al 1995; Shahinian and Silvius 1995; Huwyler et al 1996). 
This design increases the ﬂ  exibility and accessibility of the 
PEG-tethered vector and therefore facilitates its interaction 
with the biological target.
Vector-conjugated PEG-liposomes were used widely 
for tumor targeting. The speciﬁ  city and characteristics of 
these liposomal carriers is thereby given mainly by the used 
targeting vectors. Such vectors include small molecules, 
peptides or monoclonal antibodies. Representative examples 
for each of these targeting principles will be provided in the 
following sections.
Many tumor cells are characterized by an overexpression 
of the folate receptor. The fact that this receptor is responsible 
for the receptor-mediated endocytosis, and thus the cellular 
internalization of the vitamin folic acid, has established the 
possibility to deliver antineoplastic drugs, macromolecules 
as well as liposomes by this pathway (Wang and Low 1998; 
Gosselin and Lee 2002; Gabizon et al 2004). Delivery of dau-
nomycin (Pan and Lee 2005) as well as doxorubicin (Shmeeda 
et al 2006) using folate-conjugated liposomes increased the 
cytotoxicity of the encapsulated anticancer drugs in various 
tumor cells. In the latter study (Shmeeda et al 2006), mouse 
J6456 lymphoma tumor cells up-regulated for the folate 
receptor were targeted using long-circulating liposomes, 
where folate was coupled to the distal end of PEG-grafted 
phospholipids. Using folate-conjugated liposomes, increased 
intracellular accumulation of the liposomal cargo was observed International Journal of Nanomedicine 2008:3(1) 25
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in vitro as well as in a mouse ascitic tumor model. It remains to 
be elucidated, if the accumulation of liposomal carriers within 
the endosomal compartment of the target cell will be associated 
with an increased tumorcidal pharmacological effect. So far, 
efforts to accelerate intracellular drug release have focused on 
the incorporation of pH sensitive phospholipids and peptides 
in the liposomal membranes. Such pH sensitive liposomes are 
stable at physiological pH in the circulation, however, they 
disintegrate and thus release the transported drug upon expo-
sure to the acidic environment of the endosomal compartment 
(Connor and Huang 1986; Drummond et al 2000; Hilgenbrink 
and Low 2005). Another approach to modulate in vivo release 
kinetics is the use of magnetoliposomes for active targeting as 
well as magnetic particle induced hyperthermia (for a review 
see (Ito et al 2005)).
An alternative receptor, which is of interest for tumor 
targeting due to overexpression on the surface of various 
cancer cells, is the transferrin receptor. The natural ligand 
of the receptor, ie, transferrin, can be coupled to the sur-
face of pegylated liposomes to achieve tumor targeting 
(Ishida et al 2001). It is important to note, however, that 
the transferrin receptor (which has a binding constant KD of 
5.6 nM) is heavily saturated in vivo by the µM endogenous 
plasma transferrin concentrations (Pardridge 1993). This 
strong competition with endogenous transferrin leads to 
poor in vivo receptor targeting after intravenous injection. 
However, efﬁ  cient tumor targeting is possible using alterna-
tive routes of administration. This has been shown for the 
photodynamic therapy of carcinoma cells in vitro (Gijsen 
et al 2002) or in vivo in an orthotopic human AY-27 rat blad-
der tumor model, where transferrin-conjugated liposomes 
were instilled directly into the bladder of the experimental 
animals (Derycke et al 2004). Alternative indications might 
be the treatment of lung cancer, where transferrin-conjugated 
liposomes could be used to deliver cytostatic drugs by 
inhalation (Anabousi et al 2006). The limitations of the 
endogenous receptor ligand transferrin can be addressed by 
the use of speciﬁ  c monoclonal antibodies (mAb). Examples 
include the OX26 mAb directed against the rat transfer-
rin receptor (Friden et al 1991). The OX26 recognizes an 
epitope on the transferrin receptor, which is distant to the 
transferrin binding site leading to minimal competition with 
plasma transferrin and therefore allows for an intravenous 
administration of this targeting vector (Skarlatos et al 1995). 
Pegylated liposomes conjugated to the OX26 mAb (ie, 
OX26-immunoliposomes) were used previously to target 
the brain vascular endothelium in vivo (Huwyler et al 1996) 
and to transport incorporated drugs across the blood-brain 
barrier by receptor-mediated transcytosis (Cerletti et al 2000; 
Zhang et al 2003).
Similar targeting strategies, which make use of immu-
noliposomes, can be applied to the targeting of various 
tumors in vivo using tumor-speciﬁ  c antibody-vectors. The 
used antibodies can be directed against various receptors or 
surface antigens, including antibodies against the transfer-
rin receptor (Suzuki et al 1997; Xu et al 2002) or clinically 
used monoclonal antibodies (as discussed above). Examples 
include the use of Fab’ fragments of a humanized recombi-
nant MAb against the extracellular domain of HER2/neu, 
which were conjugated to sterically stabilized immunolipo-
somes and used for the targeting of HER2-overexpressing 
breast cancer cells (Kirpotin et al 1997). The signiﬁ  cantly 
increased anticancer activity in several animal xenograft 
tumor models of the immunoliposomal preparations can be 
attributed to the fact, that the immunoconjugates (as well as 
the free antibody) are internalized rapidly by the target cells 
by receptor-mediated endocytosis (Park et al 2001; Park et al 
2002). The importance of this observation is emphasized 
by studies, where liposomes conjugated to the monoclonal 
antibody OV-TL3 were used for the treatment of ovarian 
carcinoma cells in an intraperitoneal animal xenograft model 
(Vingerhoeds et al 1996). Despite efﬁ  cient targeting of the 
OA3 surface receptor on the ovarian tumor cells, no superior 
antitumor effects could be demonstrated in vitro or in vivo as 
compared to non-targeted liposomal formulations. This lack 
of enhanced efﬁ  cacy was attributed in part to the fact, that 
the cell-bound liposomes were not internalized by the target 
cells (Mastrobattista et al 1999). An interesting approach to 
overcome these limitations of surface-bound tumor mark-
ers and to exploit them for a targeting strategy is the use 
of immuno-enzymosomes (Vingerhoeds et al 1993; Bailey 
1994). Immunoliposomes are thereby not used to deliver a 
liposomal drug to its site of action but rather to transport 
pro-drug activating enzymes on their surface. Subsequent to 
liposomal tumor targeting, an anticancer prodrug matched 
with the enzyme is given, which will be converted to a 
cytotoxic compound at the tumor site. At least in different in 
vitro systems, immuno-enzymosomes were able to induce a 
marked cytotoxicity, which was superior to the one observed 
for immunoliposomes or the non-targeted liposomal enzyme 
(Fonseca et al 2003).
Perspectives
Reversal of multidrug resistance
There are two main protein superfamilies of drug transport-
ing proteins, which have been reported to interfere with the International Journal of Nanomedicine 2008:3(1) 26
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pharmacokinetics and tissue distribution of pharmaceuticals 
and in particular anticancer drugs: Members of the solute 
carrier (SLC) protein family have been classiﬁ  ed as second-
ary or tertiary active drug transporters, which are driven by 
an exchange of intracellular ions (Mizuno and Sugiyama 
2002). ATP hydrolysis is the driving force for primary drug 
transporters, belonging to the class of ATP-binding cassette 
transporters (ABC transporters). The human ABC transporter 
gene superfamily comprises currently 49 members belonging 
to eight subfamilies (Klein et al 1999; Schinkel and Jonker 
2003). A prominent and well characterized member of the 
ABC transporters is P-glycoprotein (Juliano and Ling 1976). 
The gene coding for P-glycoprotein (ABCB1, MDR1) has 
been localized in several human tissues including the liver, 
kidney, intestine and the brain (Thiebaut et al 1987). Expres-
sion of this ATP-dependent drug efﬂ  ux pump by tumor cells 
is associated with a deﬁ  ned pattern of multidrug-resistance 
(MDR or multidrug-resistance phenotype) against anticancer 
drugs including anthracyclines, anthracenes, vinca-alcaloids, 
camptothecin derivatives (topotecan), tubulin polymer-
izing drugs (colchicine and taxanes), actinomycin D, and 
epipodophyllotoxins (eg, etoposide) (Litman et al 2001). 
P-glycoprotein is expressed frequently in clinical cancers. 
The mean expression frequency of the MDR1 gene prod-
uct, as shown by statistical meta-analysis, is 38% with a 
range from 0% (prostate carcinoma) to 88% (endometrial 
carcinoma) (Efferth and Osieka 1993). Cytostatic treatment 
leads to an increase in P-glycoprotein expression in all tumor 
types analyzed in the range from 4% (sarcoma) to 51% (lung 
carcinoma) (Efferth and Osieka 1993). Inherent or acquired 
multidrug-resistance in cancer has been shown to be associ-
ated with a poor prognosis at the time of diagnosis and is 
thus a major challenge in cancer treatment.
Pharmacological reversal of MDR activity by the use 
of speciﬁ  c inhibitors of drug carriers is problematic (Sikic 
1997). The use of compounds such as the P-glycoprotein 
antagonist SDZ PSC 833, a non-immunosupressant ana-
logue of cyclosporin A, leads to a higher susceptibility 
of tumors towards chemotherapy (Boesch et al 1991). 
However, this beneﬁ  cial effect is neutralized by the fact, 
that such compounds potentiate toxic side-effects of the 
used cancer drugs in non-diseased tissues (Advani et al 
1999). This phenomenon is a consequence of inhibition 
of endogenously expressed P-glycoprotein, which has an 
important protective function in these tissues (Lemaire et al 
1996; Song et al 1999). An alternative approach to over-
come MDR could be the use of immunoliposomes, since 
this technology allows to by-pass drug transporters located 
in the plasma membrane (Suzuki et al 1997). Using anti 
transferrin receptor antibody-conjugated immunoliposomes, 
it could be shown that cellular uptake of the P-glycoprotein 
substrate digoxin by P-glycoprotein competent endothe-
lial RBE4 cells was indeed increased by a factor of 25 as 
compared to the free drug (Huwyler et al 2002). In con-
trast to the free drug, cellular accumulation of liposomal 
digoxin was thereby insensitive to co-administration of the 
P-glycoprotein inhibitor ritonavir but sensitive to nocodazole, 
a reversible inhibitor of endocytosis. Other liposome-based 
targeting strategies, such as the use of immunoliposomes 
conjugated with a monoclonal antibody directed against 
P-glycoprotein (Matsuo et al 2001), demonstrated enhanced 
cytotoxic effects in P-glycoprotein expressing tumor cell 
lines (Mamot et al 2003).
Gene therapy
Traditionally, cationic liposomes have been used for the 
transfection of cells in vitro. DNA can be complexed with 
cationic lipids leading to the formation of condensed aggre-
gates of DNA and multilamellar lipid bilayers (Spector and 
Schnur 1997). An overall positive charge of these com-
plexes enhances transfection of anionic animal target cells. 
However, a use of such cationic liposomal carriers in vivo 
is hardly possible due to their very unfavorable pharmaco-
kinetic properties: On one hand, an unspeciﬁ  c and rapid 
binding and transfection of every tissue is observed, which 
comes in contact with the cationic DNA complexes (Liu et al 
1995). On the other hand, precipitation and ﬂ  occulation into 
large aggregates of cationic DNA-lipid complexes occurs at 
their isoelectric point (Rädler et al 1997). After intravenous 
application, a massive retention by passive ﬁ  ltration of these 
aggregates is observed within the lung, which is the ﬁ  rst tis-
sue to be perfused after injection (Osaka et al 1996; Liu et al 
1997). Very recent and exciting experiments did overcome 
these problems by using pegylated immunoliposomes to 
deliver DNA expression plasmids to rodent or primate brain 
tissue (Shi and Pardridge 2000; Zhang et al 2003). Unlike cat-
ionic liposomes, this neutral and long circulating liposomal 
formulation is stable and not trapped in the lung. This high 
selectivity offers the possibility of a nonviral gene therapy 
of tumor and possibly other tissues. To this end, pegylated 
immunoliposomes were conjugated to two different mono-
clonal antibodies, which were used to target the construct to 
U87 human glioma cells implanted into the brain of immuno-
deﬁ  cient (scid) mice (Zhang et al 2003). The used antibodies 
were the rat 8D3 mAb to the mouse transferrin receptor to 
promote transfer across the mouse blood-brain barrier and International Journal of Nanomedicine 2008:3(1) 27
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the 83–14 mAb to the human insulin receptor to target the 
implanted human glioma cells within the brain parenchyma. 
The transported DNA expression plasmid did encode for a 
short hairpin RNA fragment (shRNA) designed to silence the 
expression of an oncogenic gene (human epidermal growth 
factor receptor EGFR) by RNA interference (RNAi) or post-
transcriptional gene silencing. This gene therapy resulted in 
almost 90% increase in survival time of mice with advanced 
intracranial brain cancer (Zhang et al 2003).
Clinical use of vector-conjugated 
liposomes
In view of the rapid and promising advances in the ﬁ  eld of 
speciﬁ  c liposomal tumor targeting during the last years, a 
clinical use of vector-conjugated liposomes or immunoli-
posomes should be envisaged. Recent reports indicate that 
an anti-HER2 immunoliposomal formulation was developed 
towards clinical trials using optimized protocols supporting 
large-scale production and clinical use (Park et al 2001). 
Matsumura et al (Matsumura et al 2004) have published 
the ﬁ  rst clinical trial where doxorubicin encapsulated in 
pegylated immunoliposomes was administered to twenty-
three patients suffering from advanced or recurrent gastric 
cancer refractory to conventional therapy. As a targeting 
vector, a F(ab)’ fragment of a human monoclonal antibody 
directed against a cancer cell surface antigen was used 
(Hosokawa et al 2003), which was coupled directly to the 
liposomal surface of pegylated liposomes without using a 
molecular spacer. The used PEG had an average molecular 
weight of 5 kDa. The immunoliposomal doxorubicin was 
well tolerated during a treatment regimen of up to six cycles. 
The volume of distribution (VD of approx. 40 ml/kg, ie, 
50% of blood volume) and the low plasma clearance (Cl of 
approx. 3 ml/h/kg) are comparable to the ones of doxorubi-
cin encapsulated in sterically stabilized liposomes (Gabizon 
et al 2003). It remains to be elucidated in future studies, if 
the proposed immunoliposomal formulation of doxorubicin 
might offer therapeutic advantages for the treatment of 
gastric cancer.
During the last years, liposomes as pharmaceutical drug 
carriers have received a lot of attention. Successful clinical 
applications in the ﬁ  eld of drug delivery and passive targeting 
of solid tumors have demonstrated the potential of the tech-
nology. Once optimized production processes are available, a 
new generation of vector-conjugated liposomal carriers will 
allow for an active targeting of metastatic or chemoresistant 
tumors, for which at present no efﬁ  cient therapeutic options 
are available. Further investigations and clinical trials are 
now required to optimize existing technologies and to make 
them available to cancer patients.
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